This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smits, G. J. Articles by Blaine, E. H. Search for Related Content PubMed PubMed Citation Articles by Smits, G. J. Articles by Blaine, E. H.

Hypertension, Vol 18, 17-21, Copyright © 1991 by American Heart Association

ARTICLES

Reversal of low dose angiotension hypertension by angiotensin receptor antagonists

GJ Smits, JP Koepke and EH Blaine
Cardiovascular Diseases Research, Searle Research and Development, St. Louis, Mo 63167.

During acute angiotension II (Ang II) infusion (200 ng/kg/min i.v.) into anesthetized rats, mean arterial pressure rose from 124 +/- 1 to 154 +/- 2 mm Hg. The peptidic Ang II antagonist saralasin lowered arterial pressure in a dose-dependent manner. The maximal decrease in pressure was similar to that observed after the Ang II infusion was discontinued. The nonpeptide Ang II antagonist, 4'-[( 2-butyl-4-chloro- 5-(hydroxymethyl)-1H-imidazole-1-yl] methyl) [1,1'-biphenyl] -2- carboxylic acid (SC-48742), lowered acutely elevated arterial pressure to a level similar to that on discontinuation of the angiotensin infusion. Chronic (8 days) infusion of Ang II (20 ng/kg/min i.v.) increased mean arterial pressure from 116 +/- 3 to 164 +/- 7 mm Hg, which then decreased to 121 +/- 6 mm Hg on termination of the infusion. Saralasin (10 micrograms/kg/min, a maximally effective dose during acute angiotensin infusion) decreased mean arterial pressure from 168 +/- 7 to 141 +/- 3 mm Hg, a pressure significantly higher (p less than 0.05) than the pressure observed after the angiotensin infusion was discontinued. SC-48742 decreased mean arterial pressure from 167 +/- 7 to 127 +/- 3 mm Hg, a pressure not statistically different from the minimum pressure observed after the angiotensin infusion was terminated. The mechanism of blood pressure elevation during acute high dose or chronic low dose Ang II infusion is different, the latter having a significant neural component as measured by the response to trimethaphan. The peptidic antagonist saralasin was fully effective in lowering acute angiotensin hypertension but only partially effective during chronic hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. Cataliotti, H. H. Chen, J. A. Schirger, F. L. Martin, G. Boerrigter, L. C. Costello-Boerrigter, K. D. James, K. Polowy, M. A. Miller, N. B. Malkar, et al. Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension Circulation, October 21, 2008; 118(17): 1729 - 1736. [Abstract] [Full Text] [PDF]

				S. L. Bealer Increased dietary sodium alters neural control of blood pressure during intravenous ANG II infusion Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H559 - H565. [Abstract] [Full Text] [PDF]

				F. Elijovich, H.-W. Zhao, C. L. Laffer, Y. Du, D. J. DiPette, T. Inagami, and D. H. Wang Regulation of Growth of the Adrenal Gland in DOC-Salt Hypertension: Role of Angiotensin II Receptor Subtypes Hypertension, January 1, 1997; 29(1): 408 - 413. [Abstract] [Full Text] [PDF]

				J. P. Collister, B. J. Hornfeldt, and J. W. Osborn Hypotensive Response to Losartan in Normal Rats : Role of Ang II and the Area Postrema Hypertension, March 1, 1996; 27(3): 598 - 606. [Abstract] [Full Text]